175 related articles for article (PubMed ID: 23490727)
21. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
Saramäki OR; Harjula AE; Martikainen PM; Vessella RL; Tammela TL; Visakorpi T
Clin Cancer Res; 2008 Jun; 14(11):3395-400. PubMed ID: 18519769
[TBL] [Abstract][Full Text] [Related]
22. NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K; Ospina-Klinck D; Tsourlakis MC; Koop C; Wilczak W; Adam M; Simon R; Sauter G; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Prostate; 2014 Jul; 74(10):1012-22. PubMed ID: 24789172
[TBL] [Abstract][Full Text] [Related]
23. Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression.
Graff RE; Pettersson A; Lis RT; Ahearn TU; Markt SC; Wilson KM; Rider JR; Fiorentino M; Finn S; Kenfield SA; Loda M; Giovannucci EL; Rosner B; Mucci LA
Am J Clin Nutr; 2016 Mar; 103(3):851-60. PubMed ID: 26817504
[TBL] [Abstract][Full Text] [Related]
24. Marked heterogeneity of ERG expression in large primary prostate cancers.
Minner S; Gärtner M; Freudenthaler F; Bauer M; Kluth M; Salomon G; Heinzer H; Graefen M; Bokemeyer C; Simon R; Sauter G; Schlomm T; Wilczak W
Mod Pathol; 2013 Jan; 26(1):106-16. PubMed ID: 22899295
[TBL] [Abstract][Full Text] [Related]
25. Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers.
Müller J; Ehlers A; Burkhardt L; Sirma H; Steuber T; Graefen M; Sauter G; Minner S; Simon R; Schlomm T; Michl U
Int J Cancer; 2013 Mar; 132(6):1333-40. PubMed ID: 22886792
[TBL] [Abstract][Full Text] [Related]
26. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.
Minner S; Enodien M; Sirma H; Luebke AM; Krohn A; Mayer PS; Simon R; Tennstedt P; Müller J; Scholz L; Brase JC; Liu AY; Schlüter H; Pantel K; Schumacher U; Bokemeyer C; Steuber T; Graefen M; Sauter G; Schlomm T
Clin Cancer Res; 2011 Sep; 17(18):5878-88. PubMed ID: 21791629
[TBL] [Abstract][Full Text] [Related]
27. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer.
Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J
Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146
[TBL] [Abstract][Full Text] [Related]
28. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
[TBL] [Abstract][Full Text] [Related]
29. Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C; Barreau Y; Simon R; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Sauter G; Wittmer C; Steurer S; Adam M; Huland H; Schlomm T; Tsourlakis MC; Quaas A
Hum Pathol; 2015 Apr; 46(4):514-23. PubMed ID: 25701228
[TBL] [Abstract][Full Text] [Related]
30. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells.
Gupta S; Iljin K; Sara H; Mpindi JP; Mirtti T; Vainio P; Rantala J; Alanen K; Nees M; Kallioniemi O
Cancer Res; 2010 Sep; 70(17):6735-45. PubMed ID: 20713528
[TBL] [Abstract][Full Text] [Related]
31. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
32. Relative 8q gain predicts disease-specific survival irrespective of the TMPRSS2-ERG fusion status in diagnostic biopsies of prostate cancer.
Barros-Silva JD; Ribeiro FR; Rodrigues A; Cruz R; Martins AT; Jerónimo C; Henrique R; Teixeira MR
Genes Chromosomes Cancer; 2011 Aug; 50(8):662-71. PubMed ID: 21584900
[TBL] [Abstract][Full Text] [Related]
33. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
[TBL] [Abstract][Full Text] [Related]
35. ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.
Berg KD; Vainer B; Thomsen FB; Røder MA; Gerds TA; Toft BG; Brasso K; Iversen P
Eur Urol; 2014 Nov; 66(5):851-60. PubMed ID: 24630684
[TBL] [Abstract][Full Text] [Related]
36. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
37. The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".
He H; Magi-Galluzzi C; Li J; Carver P; Falzarano S; Smith K; Rubin MA; Zhou M
Am J Surg Pathol; 2011 Apr; 35(4):608-14. PubMed ID: 21383613
[TBL] [Abstract][Full Text] [Related]
38. ERG upregulation and related ETS transcription factors in prostate cancer.
Rostad K; Mannelqvist M; Halvorsen OJ; Oyan AM; Bø TH; Stordrange L; Olsen S; Haukaas SA; Lin B; Hood L; Jonassen I; Akslen LA; Kalland KH
Int J Oncol; 2007 Jan; 30(1):19-32. PubMed ID: 17143509
[TBL] [Abstract][Full Text] [Related]
39. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
40. Emerging biological observations in prostate cancer.
Shah S; Small E
Expert Rev Anticancer Ther; 2010 Jan; 10(1):89-101. PubMed ID: 20014889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
